Results 191 to 200 of about 175,069 (261)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

open access: yesAllergy, EarlyView.
This study evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Patients who switched from LTP to donidalorsen experienced a 67.6% reduction in HAE attack rates over 52 weeks.
Marc A. Riedl   +16 more
wiley   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

open access: yesAllergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian   +18 more
wiley   +1 more source

Remission in Global Airway Diseases: EUFOREA Consensus Paper

open access: yesAllergy, EarlyView.
ABSTRACT The therapeutic goal in chronic airway diseases is shifting from symptom control to disease remission. Disease‐modifying therapies, including biologics and allergen immunotherapy, have made remission achievable in patients with severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), or allergic rhinitis (AR).
J. Christian Virchow   +22 more
wiley   +1 more source

Identification of Coagulation Phenotypes Using Viscoelastic and Conventional Assays During Veno‐Venous Extracorporeal Membrane Oxygenation: A Hierarchical Clustering Analysis

open access: yesArtificial Organs, EarlyView.
Hierarchical clustering of viscoelastic and conventional coagulation parameters identified three distinct phenotypes in V‐V ECMO patients, revealing substantial APTT–CK‐R discordance and highlighting the value of TEG‐derived markers for detecting coagulopathy not captured by standard monitoring.
Daisuke Irimada   +9 more
wiley   +1 more source

Respiratory Syncytial Virus Vaccination Is Associated With Increased Odds of Preterm Birth

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To analyse whether respiratory syncytial virus (RSV) vaccination during pregnancy increases the odds of preterm birth. Methods A rapid review and meta‐analysis was performed. The main outcome was the risk of preterm (gestational week less than 37) birth.
Ilari Kuitunen, Marjut Haapanen
wiley   +1 more source

CLINICO–Demographic Profile and Outcomes of Hospitalised Children With Diphtheria in A Tertiary Care Hospital of Peshawar

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To determine the clinico‐demographic profile and predictors of mortality in hospitalised children with diphtheria. Methods This retrospective cohort study included 202 children aged 5–16 years diagnosed with diphtheria per WHO criteria at Lady Reading Hospital, Peshawar, from January 2023 to December 2024. Data on demographics, vaccination
Amir Muhammad   +6 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy